Since the first tissue-engineered vascular graft (TEVG) was implanted in a child over a
decade ago, growth in the field of vascular tissue engineering has been driven by clinical …

One of the major causes of morbidity and mortality after the Fontan operation is
thromboembolic events (TE). To assess the current knowledge of TE after Fontan surgery, a …

Biodegradable scaffolds seeded with bone marrow mononuclear cells (BMCs) are the
earliest tissue-engineered vascular grafts (TEVGs) to be used clinically. These TEVGs …

We developed a tissue-engineered vascular graft (TEVG) for use in children and present
results of a US Food and Drug Administration (FDA)–approved clinical trial evaluating this …

OBJECTIVES: The objective of this work is to evaluate the hemodynamic performance of a
new Y-graft modification of the extracardiac conduit Fontan operation. The performance of …

Objective: To evaluate the growth potential of a tissue-engineered vascular graft (TEVG) in a
juvenile animal model. Methods: Polyglycolic acid nonwoven mesh tubes (3-cm length, 1.3 …

BACKGROUND: In the extracardiac Fontan operation, larger conduits are used when
considering the patients' growth rate. However, larger conduits may cause inefficient flow …

Objectives This study examined changes in practice and analyzed risk factors for adverse
early outcomes after Fontan surgery through use of a binational, population-based registry …

Objective Dating back to the first published report of the Fontan circulation in 1971, multiple
studies have examined the long-term results of this standard procedure for palliation of …

For over 25 years, our group has used regenerative medicine strategies to develop
improved biomaterials for use in congenital heart surgery. Among other applications, we …